Implantica AG’s RefluxStop Gains Attention at DDW Conference

VADUZ, Liechtenstein, May 27, 2025 — Implantica AG (publ.), a Swiss-based company specializing in medical implants and instruments, has reported successful pre-launch activities in the U.S. for its RefluxStop product, pending FDA approval. The company’s efforts have been met with significant interest from U.S. surgeons, as evidenced by the intensive dialogue generated at the Digestive Disease Week (DDW) conference in San Diego, California.

The DDW, recognized as the world’s largest conference in the field of digestive diseases, served as a pivotal platform for Implantica AG to showcase its RefluxStop. The conference, attended by over 13,000 leading surgeons, gastroenterologists, academics, and researchers, focused on the latest innovations and clinical data in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

Several presentations on RefluxStop were held at the conference, highlighting its unique mechanism of action and the advantages it offers in treating reflux disease. Dr. med. Zehetner, a key figure in the development and clinical application of RefluxStop, shared his real-world knowledge and clinical outcomes with top experts and leaders in the field. “The curiosity and interest were palpable as more and more surgeons and GIs throughout DDW learned about the unique mechanism of action and the advantages of the RefluxStop procedure,” Dr. Zehetner remarked. He expressed honor in sharing his insights with the esteemed attendees.

Implantica AG’s primary listing is on the Swedish Stock Exchange, and the company has shown resilience in the market with a close price of 37 SEK as of May 22, 2025. The company’s market capitalization stands at 1,629,923,120 SEK, with a 52-week high of 51.7 SEK on August 25, 2024, and a low of 22 SEK on April 6, 2025.

The successful engagement at DDW underscores the potential of RefluxStop to make a significant impact in the U.S. market, pending regulatory approval. The European real-world clinical evidence presented has already generated considerable interest, positioning Implantica AG as a key player in the medical implants and instruments sector.